Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
26
CASBF Quote, Financials, Valuation and Earnings
Last price:
$3.86
Seasonality move
:
19.62%
Day range:
$3.86 - $3.86
52-week range:
$3.20 - $6.99
Dividend yield:
3.09%
P/E ratio:
241.25x
P/S ratio:
6.40x
P/B ratio:
1.35x
Volume:
--
Avg. volume:
49
1-year change:
-16.09%
Market cap:
$953.6M
Revenue:
$148.6M
EPS (TTM):
$0.01
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CASBF
CanSino Biologics, Inc.
|
-- | -- | -- | -- | -- |
|
SVA
Sinovac Biotech Ltd.
|
-- | -- | -- | -- | -- |
|
VBIZF
Viva Biotech Holdings
|
-- | -- | -- | -- | -- |
|
WXXWY
WuXi Biologics (Cayman), Inc.
|
-- | -- | -- | -- | -- |
|
ZLAB
Zai Lab Ltd.
|
$116.5M | -$0.48 | 10.78% | -4.05% | $38.47 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CASBF
CanSino Biologics, Inc.
|
$3.86 | -- | $953.6M | 241.25x | $0.00 | 3.09% | 6.40x |
|
SVA
Sinovac Biotech Ltd.
|
$6.47 | -- | $464.9M | -- | $55.00 | 0% | 1.50x |
|
VBIZF
Viva Biotech Holdings
|
$0.3434 | -- | $724.5M | 16.20x | $0.00 | 1.01% | 3.33x |
|
WXXWY
WuXi Biologics (Cayman), Inc.
|
$8.96 | -- | $18.6B | 27.92x | $0.00 | 0% | 6.24x |
|
ZLAB
Zai Lab Ltd.
|
$20.41 | $38.47 | $2.3B | -- | $0.00 | 0% | 4.87x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CASBF
CanSino Biologics, Inc.
|
-- | 2.228 | -- | 2.94x |
|
SVA
Sinovac Biotech Ltd.
|
3.46% | 7.237 | 12.91% | 11.22x |
|
VBIZF
Viva Biotech Holdings
|
24.82% | 1.403 | -- | 1.26x |
|
WXXWY
WuXi Biologics (Cayman), Inc.
|
5.93% | 2.689 | -- | 1.98x |
|
ZLAB
Zai Lab Ltd.
|
23.86% | 0.688 | 11.48% | 2.18x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CASBF
CanSino Biologics, Inc.
|
-- | $2.1M | 0.44% | 0.57% | 3.98% | -$2.1M |
|
SVA
Sinovac Biotech Ltd.
|
-- | -- | -1.02% | -1.05% | -- | -- |
|
VBIZF
Viva Biotech Holdings
|
-- | -- | -1.17% | -1.8% | -- | -- |
|
WXXWY
WuXi Biologics (Cayman), Inc.
|
-- | -- | 7.16% | 7.53% | -- | -- |
|
ZLAB
Zai Lab Ltd.
|
$65.6M | -$69.7M | -17.96% | -22.45% | -54.4% | -$19.1M |
CanSino Biologics, Inc. vs. Competitors
-
Which has Higher Returns CASBF or SVA?
Sinovac Biotech Ltd. has a net margin of 3.58% compared to CanSino Biologics, Inc.'s net margin of --. CanSino Biologics, Inc.'s return on equity of 0.57% beat Sinovac Biotech Ltd.'s return on equity of -1.05%.
Company Gross Margin Earnings Per Share Invested Capital CASBFCanSino Biologics, Inc.-- -- $708.9M SVASinovac Biotech Ltd.-- -- $11.8B -
What do Analysts Say About CASBF or SVA?
CanSino Biologics, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Sinovac Biotech Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that CanSino Biologics, Inc. has higher upside potential than Sinovac Biotech Ltd., analysts believe CanSino Biologics, Inc. is more attractive than Sinovac Biotech Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CASBFCanSino Biologics, Inc.0 0 0 SVASinovac Biotech Ltd.0 0 0 -
Is CASBF or SVA More Risky?
CanSino Biologics, Inc. has a beta of 1.643, which suggesting that the stock is 64.291% more volatile than S&P 500. In comparison Sinovac Biotech Ltd. has a beta of 0.887, suggesting its less volatile than the S&P 500 by 11.313%.
-
Which is a Better Dividend Stock CASBF or SVA?
CanSino Biologics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 3.09%. Sinovac Biotech Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $55.00 per share. CanSino Biologics, Inc. pays -- of its earnings as a dividend. Sinovac Biotech Ltd. pays out -328.35% of its earnings as a dividend.
-
Which has Better Financial Ratios CASBF or SVA?
CanSino Biologics, Inc. quarterly revenues are $52.9M, which are larger than Sinovac Biotech Ltd. quarterly revenues of --. CanSino Biologics, Inc.'s net income of $1.9M is higher than Sinovac Biotech Ltd.'s net income of --. Notably, CanSino Biologics, Inc.'s price-to-earnings ratio is 241.25x while Sinovac Biotech Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CanSino Biologics, Inc. is 6.40x versus 1.50x for Sinovac Biotech Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CASBFCanSino Biologics, Inc.6.40x 241.25x $52.9M $1.9M SVASinovac Biotech Ltd.1.50x -- -- --
-
Which has Higher Returns CASBF or VBIZF?
Viva Biotech Holdings has a net margin of 3.58% compared to CanSino Biologics, Inc.'s net margin of --. CanSino Biologics, Inc.'s return on equity of 0.57% beat Viva Biotech Holdings's return on equity of -1.8%.
Company Gross Margin Earnings Per Share Invested Capital CASBFCanSino Biologics, Inc.-- -- $708.9M VBIZFViva Biotech Holdings-- -- $694.7M -
What do Analysts Say About CASBF or VBIZF?
CanSino Biologics, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Viva Biotech Holdings has an analysts' consensus of -- which suggests that it could fall by --. Given that CanSino Biologics, Inc. has higher upside potential than Viva Biotech Holdings, analysts believe CanSino Biologics, Inc. is more attractive than Viva Biotech Holdings.
Company Buy Ratings Hold Ratings Sell Ratings CASBFCanSino Biologics, Inc.0 0 0 VBIZFViva Biotech Holdings0 0 0 -
Is CASBF or VBIZF More Risky?
CanSino Biologics, Inc. has a beta of 1.643, which suggesting that the stock is 64.291% more volatile than S&P 500. In comparison Viva Biotech Holdings has a beta of 0.650, suggesting its less volatile than the S&P 500 by 34.961%.
-
Which is a Better Dividend Stock CASBF or VBIZF?
CanSino Biologics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 3.09%. Viva Biotech Holdings offers a yield of 1.01% to investors and pays a quarterly dividend of $0.00 per share. CanSino Biologics, Inc. pays -- of its earnings as a dividend. Viva Biotech Holdings pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CASBF or VBIZF?
CanSino Biologics, Inc. quarterly revenues are $52.9M, which are larger than Viva Biotech Holdings quarterly revenues of --. CanSino Biologics, Inc.'s net income of $1.9M is higher than Viva Biotech Holdings's net income of --. Notably, CanSino Biologics, Inc.'s price-to-earnings ratio is 241.25x while Viva Biotech Holdings's PE ratio is 16.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CanSino Biologics, Inc. is 6.40x versus 3.33x for Viva Biotech Holdings. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CASBFCanSino Biologics, Inc.6.40x 241.25x $52.9M $1.9M VBIZFViva Biotech Holdings3.33x 16.20x -- --
-
Which has Higher Returns CASBF or WXXWY?
WuXi Biologics (Cayman), Inc. has a net margin of 3.58% compared to CanSino Biologics, Inc.'s net margin of --. CanSino Biologics, Inc.'s return on equity of 0.57% beat WuXi Biologics (Cayman), Inc.'s return on equity of 7.53%.
Company Gross Margin Earnings Per Share Invested Capital CASBFCanSino Biologics, Inc.-- -- $708.9M WXXWYWuXi Biologics (Cayman), Inc.-- -- $6.6B -
What do Analysts Say About CASBF or WXXWY?
CanSino Biologics, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand WuXi Biologics (Cayman), Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that CanSino Biologics, Inc. has higher upside potential than WuXi Biologics (Cayman), Inc., analysts believe CanSino Biologics, Inc. is more attractive than WuXi Biologics (Cayman), Inc..
Company Buy Ratings Hold Ratings Sell Ratings CASBFCanSino Biologics, Inc.0 0 0 WXXWYWuXi Biologics (Cayman), Inc.0 0 0 -
Is CASBF or WXXWY More Risky?
CanSino Biologics, Inc. has a beta of 1.643, which suggesting that the stock is 64.291% more volatile than S&P 500. In comparison WuXi Biologics (Cayman), Inc. has a beta of 0.020, suggesting its less volatile than the S&P 500 by 98.002%.
-
Which is a Better Dividend Stock CASBF or WXXWY?
CanSino Biologics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 3.09%. WuXi Biologics (Cayman), Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CanSino Biologics, Inc. pays -- of its earnings as a dividend. WuXi Biologics (Cayman), Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CASBF or WXXWY?
CanSino Biologics, Inc. quarterly revenues are $52.9M, which are larger than WuXi Biologics (Cayman), Inc. quarterly revenues of --. CanSino Biologics, Inc.'s net income of $1.9M is higher than WuXi Biologics (Cayman), Inc.'s net income of --. Notably, CanSino Biologics, Inc.'s price-to-earnings ratio is 241.25x while WuXi Biologics (Cayman), Inc.'s PE ratio is 27.92x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CanSino Biologics, Inc. is 6.40x versus 6.24x for WuXi Biologics (Cayman), Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CASBFCanSino Biologics, Inc.6.40x 241.25x $52.9M $1.9M WXXWYWuXi Biologics (Cayman), Inc.6.24x 27.92x -- --
-
Which has Higher Returns CASBF or ZLAB?
Zai Lab Ltd. has a net margin of 3.58% compared to CanSino Biologics, Inc.'s net margin of -39.51%. CanSino Biologics, Inc.'s return on equity of 0.57% beat Zai Lab Ltd.'s return on equity of -22.45%.
Company Gross Margin Earnings Per Share Invested Capital CASBFCanSino Biologics, Inc.-- -- $708.9M ZLABZai Lab Ltd.51.15% -$0.46 $939.8M -
What do Analysts Say About CASBF or ZLAB?
CanSino Biologics, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Zai Lab Ltd. has an analysts' consensus of $38.47 which suggests that it could grow by 88.47%. Given that Zai Lab Ltd. has higher upside potential than CanSino Biologics, Inc., analysts believe Zai Lab Ltd. is more attractive than CanSino Biologics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CASBFCanSino Biologics, Inc.0 0 0 ZLABZai Lab Ltd.8 1 0 -
Is CASBF or ZLAB More Risky?
CanSino Biologics, Inc. has a beta of 1.643, which suggesting that the stock is 64.291% more volatile than S&P 500. In comparison Zai Lab Ltd. has a beta of 0.859, suggesting its less volatile than the S&P 500 by 14.084%.
-
Which is a Better Dividend Stock CASBF or ZLAB?
CanSino Biologics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 3.09%. Zai Lab Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CanSino Biologics, Inc. pays -- of its earnings as a dividend. Zai Lab Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CASBF or ZLAB?
CanSino Biologics, Inc. quarterly revenues are $52.9M, which are smaller than Zai Lab Ltd. quarterly revenues of $128.2M. CanSino Biologics, Inc.'s net income of $1.9M is higher than Zai Lab Ltd.'s net income of -$50.6M. Notably, CanSino Biologics, Inc.'s price-to-earnings ratio is 241.25x while Zai Lab Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CanSino Biologics, Inc. is 6.40x versus 4.87x for Zai Lab Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CASBFCanSino Biologics, Inc.6.40x 241.25x $52.9M $1.9M ZLABZai Lab Ltd.4.87x -- $128.2M -$50.6M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
51
AAOI alert for Apr 4
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Buy
59
SBAC alert for Apr 4
SBA Communications Corp. [SBAC] is up 18.96% over the past day.
Buy
55
VSAT alert for Apr 4
ViaSat, Inc. [VSAT] is up 18.73% over the past day.
